Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Palo Alto Investors LP
Form 13F · Q2 2026

Palo Alto Investors LP

CIK 1306923Filed 2026-08-1913F-HR/A View the filing on EDGAR ↗
$724M
Reported book value
52
Positions
12
Quarters on record
Top 50
Positions

Palo Alto Investors LP — holdings

Top 50 positions of 52, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1PTCT Ptc Therapeutics Inc918,846−0.3%$75M10.4%
2ACAD Acadia Pharmaceuticals Inc2.9M−0.3%$72M10.0%
3INSM Insmed Inc413,980−0.3%$44M6.1%
4MIRM Mirum Pharmaceuticals Inc348,808+7.3%$41M5.6%
5ANAB Anaptysbio Inc603,489−5.4%$41M5.6%
6BMRN Biomarin Pharmaceutical Inc682,777−0.4%$39M5.4%
7DYN Dyne Therapeutics Inc1.6M−0.3%$37M5.1%
8UTHR United Therapeutics Corp Del62,587−0.4%$34M4.7%
9IRON Disc Medicine Inc416,646+3.7%$30M4.2%
10BIIB Biogen Inc140,279−0.3%$30M4.2%
11IOVA Iovance Biotherapeutics Inc5.3M−16.6%$22M3.0%
12RARE Ultragenyx Pharmaceutical In596,495+0.0%$20M2.8%
13NVCR Novocure Ltd1.3M+0.0%$19M2.7%
14SNDX Syndax Pharmaceuticals Inc864,986+0.0%$19M2.6%
15ANNX Annexon Inc2.9M+0.0%$17M2.3%
16BCAX Bicara Therapeutics Inc550,408+0.0%$16M2.3%
17CDNA Caredx Inc531,870+0.0%$15M2.1%
18CLDX Celldex Therapeutics Inc New399,856+34.9%$15M2.1%
19CMPX Compass Therapeutics Inc5.8M+285.1%$13M1.8%
20ALKS Alkermes Plc242,560+0.0%$13M1.8%
21TRAX First Tracks Biotherapeutics603,489—$12M1.7%
22PRTA Prothena Corp Plc1.1M−5.4%$11M1.5%
23TVTX Travere Therapeutics Inc167,525−27.3%$10M1.3%
24TSHA Taysha Gene Therapies Inc1.4M+0.0%$9M1.3%
25ACRS Aclaris Therapeutics Inc1.6M+0.0%$9M1.2%
26AGIO Agios Pharmaceuticals Inc213,601+0.0%$8M1.1%
27CAPR Capricor Therapeutics Inc229,763+0.0%$6M0.8%
28ALGN Align Technology Inc31,389−24.4%$5M0.7%
29ORKA Oruka Therapeutics Inc33,546−44.1%$3M0.4%
30XENE Xenon Pharmaceuticals Inc51,345+0.0%$3M0.4%
31NBIX Neurocrine Biosciences Inc18,117+0.0%$3M0.4%
32EW Edwards Lifesciences Corp33,640+0.0%$3M0.4%
33STOK Stoke Therapeutics Inc84,631+0.0%$3M0.4%
34CYTK Cytokinetics Inc32,195+0.0%$3M0.4%
35PYXS Pyxis Oncology Inc864,277−14.5%$3M0.4%
36EHTH Ehealth Inc1.5M+0.0%$2M0.3%
37CRSP Crispr Therapeutics Ag39,605+0.0%$2M0.3%
38SGMT Sagimet Biosciences Inc250,000—$2M0.3%
39NUVB Nuvation Bio Inc326,609−35.8%$2M0.3%
40BNTX Biontech Se19,614+0.0%$2M0.3%
41CMPS Compass Pathways Plc115,616+0.0%$2M0.2%
42HUM Humana Inc3,985+0.0%$2M0.2%
43NAMS Newamsterdam Pharma Company44,359—$2M0.2%
44VSTM Verastem Inc309,685+25.8%$1M0.2%
45MDGL Madrigal Pharmaceuticals Inc1,787+0.0%$959,5300.1%
46URGN Urogen Pharma Ltd24,500+0.0%$901,6000.1%
47BCYC Bicycle Therapeutics Plc201,890+0.0%$856,0140.1%
48XERS Xeris Biopharma Holdings Inc104,410+0.0%$826,9270.1%
49ABEO Abeona Therapeutics Inc108,865+0.0%$672,7860.1%
50INSPIRE MED SYS INC Inspire Med Sys Inc8,772+0.0%$391,3190.1%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.